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Brief Report
PLATELETS AND THROMBOPOIESIS
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Key Points
• Novel FLI1 and RUNX1
alterations were identified in 6
of 13 patients with excessive
bleeding and platelet granule
secretion defects.
• Two FLI1 alterations
predicting amino acid
substitutions in the DNA-
binding domain of FLI1
abolished transcriptional
activity of FLI1.
We analyzed candidate platelet function disorder genes in 13 index cases with a history of
excessive bleeding in association with a significant reduction in dense granule secretion
and impaired aggregation to a panel of platelet agonists. Five of the index cases also had
mild thrombocytopenia. Heterozygous alterations in FLI1 and RUNX1, encoding Friend
leukemia integration 1 and RUNT-related transcription factor 1, respectively, which have
a fundamental role in megakaryocytopoeisis, were identified in 6 patients, 4 of whom had
mild thrombocytopenia. Two FLI1 alterations predicting p.Arg337Trp and p.Tyr343Cys
substitutions in the FLI1 DNA-binding domain abolished transcriptional activity of FLI1. A
4-bp deletion in FLI1, and 2 splicing alterations and a nonsense variation inRUNX1, which
were predicted to cause haploinsufficiency of either FLI1 or RUNX1, were also identified.
Our findings suggest that alterations in FLI1 and RUNX1may be common in patients with
platelet dense granule secretion defects and mild thrombocytopenia. (Blood. 2013;
122(25):4090-4093)
Introduction
Inherited platelet function disorders (PFDs), which cause excessive
bleeding, are heterogeneous and can seldom be linked to a causative
gene using clinical and laboratory phenotype alone.1 The advent of
techniques allowing selective capture and enrichment of target gene
sequences, coupled with next-generation sequencing (NGS) tech-
nology, has facilitated the rapid identiﬁcation of disease-associated
variants by enabling the simultaneous analysis of large numbers of
genes. We have used NGS to investigate index cases from 13
unrelated families recruited to the UK Genotyping and Phenotyping
of Platelets (UK GAPP) study2 with signiﬁcantly reduced platelet
dense granule secretion using lumi-aggregometry.
Study design
Recruitment of patients and platelet phenotyping
Index cases and affected relatives from a subgroup of 13 families, recruited
to the UK GAPP study on the basis of excessive clinical bleeding and
a suspicion of an inherited platelet disorder, were investigated. These in-
dividuals were diagnosed with a platelet dense granule secretion defect
following platelet phenotyping but had no other features of Hermansky-
Pudlak syndrome. The inclusion and exclusion criteria for recruitment to
the study, and the criteria for diagnosis of a dense granule secretion defect,
have been described.3 Platelet aggregation and adenosine triphosphate (ATP)
secretion were assessed in platelet-rich plasma using a rationalized panel
of platelet agonists and a dual-channel Chronolog lumi-aggregometer.3
This study was approved by the National Research Ethics Service Committee
West Midlands–Edgbaston (REC reference: 06/MRE07/36) and conducted in
accordance with the Declaration of Helsinki.
Analysis of candidate genes
Genomic DNA was isolated from peripheral blood, and NGS of candidate
PFD genes was undertaken on an ABI-SOLiD31 or an Illumina Genome
Analyzer IIx platform.2,4 Novel sequence variations identiﬁed by NGS
were conﬁrmed by conventional Sanger sequencing. Where possible, patients
were selected for NGS analysis on the basis of having an affected relative
who was also available for study.
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Detection of MYH10 in platelets
Nonmuscle myosin heavy chain IIB (MYH10) was detected in platelets by
sodium dodecyl sulfate–polyacrylamide gel electrophoresis and immuno-
blotting as described.5
Results and discussion
To date, 366 patients, from 292 unrelated families, have been re-
cruited to theUKGAPP study, of whom56 (15%) have been classiﬁed
as having a secretion defect. NGS analysis of candidate PFD genes
was undertaken in 13 of the patients with defects in secretion, whowere
selected, where possible, on the basis of having an affected relativewho
was also available for study. Novel heterozygous alterations in either
the FLI1 or RUNX1 gene were identiﬁed in 6 of the families (F1 to
F6) (Table 1). Two nonsynonymous FLI1 alterations, c.1009C.T
and c.1028A.G, predicting p.R337W and p.Y343C substitutions in
the highly conserved DNA-binding domain of FLI1, were identiﬁed
in affected members of F1 and F2, and a 4-bp frameshift deletion in
FLI1 (c.992-995del; p.Asn331Thrfs*4) was present in both affected
members of F3. Three RUNX1 variations predicted to cause RUNX1
haploinsufﬁciency were identiﬁed; donor splice site transversions,
c.50811G.T and c.35111G.T, were detected in F4 and F5,
respectively, and a nonsense mutation in codon 106 (c.317G.A;
p.Trp106Stop) was detected in the index case from F6.
The presence of an FLI1 or RUNX1 alteration was associated
with symptoms of excessive bleeding in all index cases, and the
patients’ affected family members, and with mild thrombocytopenia
in 5 of the families (Table 1; supplemental Figure 1, see the Blood
Web site). In F4, the splice site alteration in RUNX1 was associated
with a normal platelet count in the index case, but with throm-
bocytopenia in 2 affected relatives. The missense variations in FLI1
were also associated with alopecia, eczema or psoriasis, and
recurrent viral infections in affected individuals in F1, and with
mild thrombocytopenia, alopecia, and eczema in the affected
individuals in F2 (Figure 1A-B).
Examination of platelet secretion and aggregation in all subjects
carrying FLI1 or RUNX1 defects consistently revealed the pre-
dominant platelet abnormality to be a signiﬁcant reduction in
platelet ATP secretion in response to all agonists tested (Figure 1C,
Table 1, supplemental Figure 2, and data not shown). As reported
previously for patients with dense granule secretion defects, reduc-
tions in platelet aggregation in response to collagen and PAR-1 were
observed in some, but not all, subjects and were usually more apparent
at low or intermediate agonist concentrations (data not shown).3
FLI1 is a member of the ETS (E–twenty six) family of tran-
scription factors, which is expressed primarily in hematopoietic cells
and regulates genes expressed both early and late in megakaryocy-
topoiesis, including GP6.6,7,8-10 Patients with Paris-Trousseau syn-
drome (PTS), who are hemizygous for FLI1 as a result of a deletion of
chromosome 11q23, have an increased tendency to bleed, which is
associated with thrombocytopenia, and enlarged platelets displaying
gianta-granules.10-12 It is thought that transientmonoallelic expression
of FLI1 at an early stage during megakaryocytopoiesis, coupled with
hemizygous loss of FLI1 in patients with PTS, which results in a
complete lack of FLI1 expression, accounts for the generation of 2
distinct subpopulations of normal and immature megakaryocytes in
patients with PTS.10 The identiﬁcation of alterations predicting
substitutions in the DNA-binding domain of FLI1 and their asso-
ciation with symptoms in 2 families suggests a role for FLI1 in the
pathogenesis of bleeding in these families.
We investigated whether the p.R337W and p.Y343C substitu-
tions could alter the DNA-binding capacity of FLI1 by examining
the ability of the recombinant FLI1 variants to bind to an ETS site in
the GP6 promoter using the dual-luciferase reporter assay to measure
Table 1. Genotypic and phenotypic characteristics of subjects with platelet dense granule secretion defects
Family (F)/patient
identification* FLI1 or RUNX1 alteration† Effect
Platelet count
(3 109/L)‡
Mean platelet
volume (fL)
ATP secretion
(nmol/1 3 108 platelets)§
F1; II.1 FLI1; c.1009 C.T p.Arg337Trp 244 10.3 0.37
F1; III.1 FLI1; c.1009 C.T p.Arg337Trp 180 10.5 0.07
F2; II.5 FLI1; c.1028 A.G p.Tyr343Cys 92 8.8 ND||
F2; III.1 FLI1; c.1028 A.G p.Tyr343Cys 117 8.6 ND||
F3.1 FLI1; c.992-995del p.Asn331Thrfs*4 142 11.4 0.38
F3.2 FLI1; c.992-995del p.Asn331Thrfs*4 157 11.8 0.57
F4.1 RUNX1; c.50811 G.T Splicing 302 7.3 0.32
F4.2 RUNX1; c.50811 G.T Splicing 70 7.5 ND
F4.3 RUNX1; c.50811 G.T Splicing 130 7.1 0.62
F5 RUNX1; c.35111G.T Splicing 139 8.0 0.35
F6.1 RUNX1; c.317 G.A p.Trp106Stop 100 8.0 0.25
F7 – – 233 8.5 0.57
F8 – – 190 8.5 ND
F9 – – 205 8.4 0.48
F10 – – 370 8.6 0.31
F11 – – 225 NA 0.63
F12 – – 245 NA 0.52
F13 – – 114 10.9 0.12
Heterozygous nucleotide changes present in FLI1 and RUNX1 and their predicted effects on the resulting RNA or protein are shown.
NA, not available; ND, not detectable.
*Index cases are indicated in bold font.
†Alterations are numbered according to positions in the NM_002017.3 and NM_001754 transcripts for FLI1 and RUNX1, respectively.
‡Mean platelet counts are shown, the normal reference range is 150 3 109 to 400 3 109 platelets per L, and thrombocytopenia is defined as platelet count ,150 3 109
platelets per L.
§ATP secreted in response to 100 mM of PAR-1 receptor–specific peptide SFLLRN; fifth percentile in healthy volunteers is 0.82 nmol/1 3 108 platelets.
||ATP secretion was measured in response to 1 U/mL of thrombin in the center where these subjects were recruited, against a normal reference range of 0.73 to 1.80
nmol/1 3 108 platelets.
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GP6 promoter activity. There was a complete loss in the ability of the
R337W and Y343C FLI1 variants to induce GP6 promoter activity
compared with that of WT-FLI1 (P, .001; Figure 1E). Furthermore,
coexpression of either the R337W or the Y343C variant withWT-FLI1,
to mimic heterozygosity, resulted in signiﬁcant reductions in the
transcriptional activity to;60% of that of WT-FLI1 alone (P, .01),
indicating that these mutations disrupt DNA binding of FLI1 and will
cause a reduction in activation of megakaryocyte-speciﬁc genes
(Figure 1E). Of interest is a previous study, which showed that R337
is critical for the function of nuclear localization signal 2 of FLI1 and
that an R337A substitution caused a reduction in nuclear accumu-
lation of FLI1.13 However, as with the R337W variant, the R337A
substitution was shown to disrupt the DNA-binding ability of FLI1
and, consequently, to downregulate expression of FLI1-inducible
megakaryocyte-speciﬁc genes.13
As a member of the RUNT family of transcription factors, the
role of RUNX1 in regulating megakaryopoiesis and platelet formation
is well established. RUNX1 has been shown to cooperate with FLI1 in
the late stages of megakaryopoiesis.14,15 Inherited RUNX1 muta-
tions are recognized to lead to autosomal dominant thrombocy-
topenia and impaired platelet function and are associated with a
propensity to myelodysplastic syndrome and acute myeloid leuke-
mia.1 RUNX1-mediated silencing of the MYH10 gene is required for
the switch from mitosis to endomitosis during megakaryocyte matu-
ration. The persistence of MYH10 in platelets was recently proposed
as a biomarker for RUNX1 alterations in patients with familial
thrombocytopenia and for FLI1 deletions in PTS.5,16 The detection
of MYH10 in platelets from patients carrying the p.Tyr343Cys and
the p.Asn331Thrfs*4 FLI1 variations conﬁrms the use of MYH10
detection as a biomarker for FLI1 alterations (Figure 1F). Indeed,
immunoblot detection of MYH10 expression in platelets would be
a useful initial screening test for inherited platelet disorders caused
by abnormalities in RUNX1 or FLI1. Dosage of RUNX1 is thought to
contribute to the risk of AML because missense mutations that result
Figure 1. Excessive bleeding and platelet dense granule secretion defects are associated with heterozygous mutations in FLI1 and RUNX1. (A-B) Pedigrees
showing inheritance of mild bleeding, alopecia totalis, and other clinical features in families 1 (A) and 2 (B). Individuals heterozygous for the c.1009C.T and c.1028A.G
transitions in FLI1 are indicated. Lines through symbols indicate deceased individuals. In panel A, individuals with bleeding symptoms, alopecia, and confirmed platelet dense
granule secretion defects are indicated by black filled symbols. An asterisk indicates the presence of eczema and a history of recurrent viral infections. The presence of
psoriasis is indicated by a “1” sign. In panel B, individuals with bleeding symptoms and alopecia are indicated by black or gray filled symbols. Black filled symbols indicate
individuals with confirmed platelet dense granule secretion defect and mild thrombocytopenia. An asterisk indicates a history of infective endocarditis, and the presence of
eczema and colitis is indicated by a “1” sign. (C) ATP secretion in response to 100 mM PAR1 peptide in 2 members of F1 with the c.1009C.T transition in FLI1 and 3
members of F4 with the c.50811G.T transversion in RUNX1 alongside controls. (D) Schematic diagram of RUNX1 and FLI1 showing the regions of the proteins affected by
mutations identified in this study. Intronic mutations, predicted to interfere with splicing of the RUNX1 RNA, are shown in italics. (E) HEK293T cells were cotransfected with
wild-type (WT) and variant FLI1 constructs, or combinations thereof, and pGL3.10-GP6-luciferase and pRLnull-Renilla reporters as shown, and firefly and Renilla luciferase
expression assessed in cell lysates 48 hours later. Data represent the means (6 standard error of the mean) of 3 independent experiments; **P, .01; ***P, .001. (F) MYH10
protein expression in platelets from patients with FLI1 mutations (F2.1 and F2.2 with p.Tyr343Cys FLI1 mutation; F3.1 and F3.2 with p.Asn331Thrfs*4 FLI1 mutation) and
a healthy control.
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in variants that can heterodimerize with normal RUNX1 and act in
a dominant-negative manner to compete with the normal protein
have been reported to be associated with a higher risk of hematologic
malignancy than mutations resulting in haploinsufﬁciency.17 The
absence of hematologic malignancies to date in the 3 families with
RUNX1 mutations identiﬁed in this study, which were all predicted
to result in haploinsufﬁciency, would support this observation.
The identiﬁcation of RUNX1 or FLI1 alterations in 6 of 13
unrelated index cases with dense granule secretion disorder, 4 of
whom had thrombocytopenia, suggests that defects in these genes
will account for a signiﬁcant proportion of patients with defects in
platelet granule secretion and excessive bleeding.
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